Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

Table 4 Subgroup analysis on prognosis

	No. of studies	Rate	95%CI	I²%	No. of studies	Rate	95%CI	I²%^a
dMMR-MSI-H ≥ 5%					dMMR-MSI-H<5%
OS	4	0.79	0.72-0.85	54.96	3	0.34	0.05-0.72	-
PFS	5	0.57	0.44-0.69	88.85	4	0.17	0.01-0.46	92.19
PD-1					PD-L1
OS	6	0.72	0.6-0.82	82.7	1	0.11	0.05-0.19	-
PFS	8	0.39	0.23-0.56	93.87	1	0.43	0.32-0.54	-
Monotherapy					Combination therapy
OS	3	0.62	0.41-0.80	-	4	0.62	0.2-0.95	98.03
PFS	4	0.37	0.21-0.54	90.64	5	0.43	0.19-0.68	94.78

^aI² cannot be calculated because the number of studies is 3 or less than 3. One-year overall survival rate (OS), one-year progression-free survival rate (PFS)

ISSN: 1477-7819